Table 3.
No association between KIR–ligand genotype and KIR haplotype with clinical outcome for RCC patients receiving HD-IL2 was found
| KIR–ligands presenta | KIR–ligand missinga | p value* | Haplotype-A | Haplotype-B | p value* | ||
|---|---|---|---|---|---|---|---|
| Maximum tumor shrinkage (% shrinkage) | n | 41 | 62 | 0.45 | 36 | 68 | 0.65 |
| Mean | 19.0 | 9.2 | 9.0 | 15.0 | |||
| SD | 63.4 | 64.0 | 61.7 | 64.5 | |||
| Progression-free survival (in months) | n | 42 | 63 | 0.47 | 37 | 69 | 0.38 |
| # of events | 37 | 60 | 36 | 62 | |||
| Median PFS (95 % CI) | 4.2 (2.3–5.9) | 4.0 (2.3–4.8) | 4.2 (2.3–5.3) | 4.0 (2.3–5.9) | |||
| Overall survival (in months) | n | 42 | 63 | 0.63 | 37 | 69 | 0.74 |
| # of events | 27 | 43 | 26 | 45 | |||
| Median OS (95 % CI) | 38.1 (26.7–61.1) | 48.8 (32.5–56.0) | 42.6 (22.5–61.1) | 47.7 (32.5–56.0) |
a All KIR–ligands present versus any KIR–ligand missing (see method section “Algorithms for genotype categorization”)
* Linear regression models were used for maximum tumor shrinkage analyses; log-rank tests and Cox proportional hazards regression models were used for PFS and OS analyses